<DOC>
	<DOCNO>NCT01793818</DOCNO>
	<brief_summary>Tat Oyi vaccination seropositive patient could help immune system recognize neutralize Tat . The neutralization extra cellular Tat help cellular immune response eliminate HIV-1 infected cell .</brief_summary>
	<brief_title>Evaluation Seropositive Patients Synthetic Vaccine Targeting HIV Tat Protein</brief_title>
	<detailed_description>The protocol get favorable judgment ethic committee ( CPP SudMed 2 ) November 9th , 2012 authorized French drug agency ( ANSM ) January 24th , 2013 . It propose HIV-1 infect volunteer participate phase I/II clinical trial test Tat Oyi vaccine . Volunteers undetectable viremia ( low 40 copies/ml ) level CD4 cell higher 350 /mm3 since least one year Anti Retroviral Treatment ( ART ) . It randomize double blind clinical trial placebo . Main Objective : No undesirable event due vaccination viremia remain &lt; 100 copies/ml interruption cART . Secondary objective : An immune response Tat characterize cross recognition Tat variant representative five main HIV-1 clade . Main parameter evaluation : Plasma viremia . Secondary parameter evaluation : Detection ELISA antibodies able recognize Tat variant representative five main HIV-1 clade .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 18 64 year old pre inclusion visit . Documented HIV1 Infection Preferentially , group A patient CDC classification group C patient . HIV1 patient treat three antiretroviral drug since 12 month change since three month undetectable viremia since 12 month . HIV1 Chronic infection define positive HIV1 ELISA HIV1 proteins characterize full HIV1 Western blot . Stable undetectable plasmatic HIV RNA ( low 40 copies/ml ) since 12 month . Lymphocyte CD4 cell higher 350/mm3 NADIR high 200/mm3 since 12 month . Free engagement , fully explain write patient signature inclusion visit test require clinical trial . Patient affiliate social security system . No vaccination influenza pathogen since three month . No chemotherapy treatment corticosteroid HIV1 patient abstinent former drug user drug user follow substitution training . HIV1 patient protect regard French law ( article L11215 , L11216 , L11217 , L11218 &amp; L11222 ) No HIV1 infection Patient infect HIV2 Patient HIV1 primo infection recently primo infection Patient symptomatic primo infection CD4 cell lower 200/mm3 Women sexually active efficient contraception Pregnant woman brass feed . Patient opportunistic infection CDC group C. Patient cancer and/or chemotherapy radiotherapy . Patient evolutive psychiatric pathology Patient HBV and/or HCV positive Patient ELISA positive HTLV1 Patient cirrhotic ( Child Pugh level A , B C ) Patient criminal investigation Patients abnormal blood formulation Patient participate another clinical research</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Tat</keyword>
</DOC>